Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 26, 2018. The document serves as a transaction notification regarding share allocations for Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs), specifically Independent Non-Executive Directors.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific equity transactions.
| Transaction Date | Instrument | Price | Total Volume |
|---|---|---|---|
| April 25, 2018 | Ordinary Shares (GBP) | £14.45 | 6,379.152 shares |
| April 25, 2018 | American Depositary Shares (USD) | $40.33 | 3,746.376 ADSs |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine share allocation transactions for the service period of January 1, 2018, to March 31, 2018 (and one instance for October 1, 2017, to December 31, 2017).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of director share acquisitions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions are acquisitions of notional shares under share allocation arrangements for Independent Non-Executive Directors.
- Participants: Transactions involved Sir Philip Hampton, Professor Sir Roy Anderson, Mr Vindi Banga, Dr Vivienne Cox, Ms Lynn Elsenhans, Dr Laurie Glimcher, Dr Jesse Goodman, Ms Judy Lewent, and Mr Urs Rohner.
- Valuation: Ordinary Shares were valued at £14.45 and ADSs at $40.33 on the transaction date.
- Scope: This filing does not reflect the company's Q1 2018 financial performance; investors should refer to the Form 20-F or quarterly press releases for operational results.